Error loading player: No playable sources found

212

Providing Hope: Evusheld Administration for COVID-19 Pre-Exposure Prophylaxis in Vulnerable Patient Populations

Date
April 13, 2023
Credits
0.75 CH | Expired April 15, 2025
$38
Standard Price
Members save $13

In 2022, the FDA issued emergency use authorization for administration of Evusheld, comprised of two monoclonal antibody medications that help minimize the risk of severe COVID-19 disease in immunocompromised patients. Once Evusheld became available, nurses at a large academic medical center researched the medication and conducted education on safety, efficacy, and administration. Shortly thereafter, administration of Evusheld was implemented within the existing special pathogens clinic and offered to physician-identified patients with the highest risk of severe COVID-19 infection for whom the vaccine would be ineffective. This session discusses the patient response and efficacy in preventing COVID-19 infection in the patients who have received it.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 4/15/2025.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speaker Disclosures:
There are no speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the American Academy of Ambulatory Care Nursing (AAACN).

Anthony J. Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

AAACN is a provider approved by the California Board of Registered Nursing, provider number CEP 5366.

Learning Outcome:
After completing this learning activity, the participant will be able to describe the role and efficacy of a monoclonal antibody medication in the prevention of severe cases of COVID-19 in immunocompromised and at-risk patients.

Speakers

Speaker Image for Amy Brewer
Amy Brewer, MSN, RN
Director of Ambulatory Nursing, UT Southwestern Medical Center
Speaker Image for Vashti Hassanizadeh
Registered Nurse, UT Southwestern Medical Center

Related Products

Thumbnail for Medical Assistant Apprenticeship Program
Medical Assistant Apprenticeship Program
This session shares how a medical assistant apprenticeship program at one academic medical center aims to simultaneously address the MA vacancy rate while promoting top of license work…
Thumbnail for Primary Care Nursing of the Future: Creating a Vision
Primary Care Nursing of the Future: Creating a Vision
This session addresses how classification of types of services provided by nurses in the primary care setting, along with the time required to provide these services, provides a foundation for reimbursement for nursing services…
Thumbnail for Inclusivity: A High-Impact Independent Nursing Intervention
Inclusivity: A High-Impact Independent Nursing Intervention
Brosschot’s Generalized Unsafety Theory of Stress (GUTS) offers new insights and a mechanism through which health care providers, including RNs, may intervene to improve health outcomes of patients from minority communities…
Thumbnail for Career Pathing Current Employees to the Role of a Medical Assistant
Career Pathing Current Employees to the Role of a Medical Assistant
A health care organization recognized that staff may wish to pursue a more clinical-focused career path but may lack the time, support, or resources to do so…
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.